|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888
|
|
G
|
Acacb
|
acetyl-CoA carboxylase beta
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr12:48,026,394...48,138,214
Ensembl chr12:48,026,394...48,138,214
|
|
G
|
Acly
|
ATP citrate lyase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccn2
|
cellular communication network factor 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976
|
|
G
|
Chrna7
|
cholinergic receptor nicotinic alpha 7 subunit
|
multiple interactions
|
ISO
|
beta-thujone inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]; beta-thujone inhibits the reaction [Choline results in increased activity of CHRNA7 protein]
|
CTD |
PMID:28395994 |
|
NCBI chr 1:126,123,425...126,249,181
Ensembl chr 1:126,123,425...126,446,858
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Cpt1a
|
carnitine palmitoyltransferase 1A
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326
|
|
G
|
Cpt2
|
carnitine palmitoyltransferase 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Dgat1
|
diacylglycerol O-acyltransferase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016
|
|
G
|
Fasn
|
fatty acid synthase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
G
|
Foxo1
|
forkhead box O1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419
|
|
G
|
Gabra1
|
gamma-aminobutyric acid type A receptor subunit alpha 1
|
multiple interactions
|
ISO
|
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
|
CTD |
PMID:15588619 |
|
NCBI chr10:27,096,731...27,152,563
Ensembl chr10:27,096,740...27,152,442
|
|
G
|
Gabrb2
|
gamma-aminobutyric acid type A receptor subunit beta 2
|
multiple interactions
|
ISO
|
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
|
CTD |
PMID:15588619 |
|
NCBI chr10:27,438,127...27,657,680
Ensembl chr10:27,438,238...27,655,171
|
|
G
|
Gabrg2
|
gamma-aminobutyric acid type A receptor subunit gamma 2
|
multiple interactions
|
ISO
|
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
|
CTD |
PMID:15588619 |
|
NCBI chr10:26,876,926...26,965,523
Ensembl chr10:26,876,926...26,965,523
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Mlycd
|
malonyl-CoA decarboxylase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr19:64,356,582...64,372,447
Ensembl chr19:64,356,223...64,372,446
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Snai1
|
snail family transcriptional repressor 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:176,667,476...176,671,965
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Zeb1
|
zinc finger E-box binding homeobox 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745
|
|
G
|
Zeb2
|
zinc finger E-box binding homeobox 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:49,624,028...49,754,323
Ensembl chr 3:49,624,028...49,754,323
|
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888
|
|
G
|
Acacb
|
acetyl-CoA carboxylase beta
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr12:48,026,394...48,138,214
Ensembl chr12:48,026,394...48,138,214
|
|
G
|
Acly
|
ATP citrate lyase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccn2
|
cellular communication network factor 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col1a2
|
collagen type I alpha 2 chain
|
affects expression
|
ISO
|
Camphor analog affects the expression of COL1A2 mRNA
|
CTD |
PMID:24704097 |
|
NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995
|
|
G
|
Cpt1a
|
carnitine palmitoyltransferase 1A
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326
|
|
G
|
Cpt2
|
carnitine palmitoyltransferase 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
decreases activity
|
EXP
|
Camphor results in decreased activity of CYP2B1 protein
|
CTD |
PMID:9242356 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
multiple interactions
|
ISO
|
Camphor inhibits the reaction [CYP2B6 protein results in increased hydrolysis of Bupropion]
|
CTD |
PMID:18611395 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Dgat1
|
diacylglycerol O-acyltransferase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016
|
|
G
|
Esr1
|
estrogen receptor 1
|
multiple interactions
|
ISO
|
Camphor binds to and results in increased activity of ESR1 protein
|
CTD |
PMID:27633901 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
Fasn
|
fatty acid synthase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
G
|
Foxo1
|
forkhead box O1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419
|
|
G
|
Gabra1
|
gamma-aminobutyric acid type A receptor subunit alpha 1
|
multiple interactions
|
ISO
|
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
|
CTD |
PMID:15588619 |
|
NCBI chr10:27,096,731...27,152,563
Ensembl chr10:27,096,740...27,152,442
|
|
G
|
Gabrb2
|
gamma-aminobutyric acid type A receptor subunit beta 2
|
multiple interactions
|
ISO
|
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
|
CTD |
PMID:15588619 |
|
NCBI chr10:27,438,127...27,657,680
Ensembl chr10:27,438,238...27,655,171
|
|
G
|
Gabrg2
|
gamma-aminobutyric acid type A receptor subunit gamma 2
|
multiple interactions
|
ISO
|
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
|
CTD |
PMID:15588619 |
|
NCBI chr10:26,876,926...26,965,523
Ensembl chr10:26,876,926...26,965,523
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Mlycd
|
malonyl-CoA decarboxylase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr19:64,356,582...64,372,447
Ensembl chr19:64,356,223...64,372,446
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO
|
Camphor inhibits the reaction [cinnamaldehyde results in increased activity of MPO protein]
|
CTD |
PMID:21466812 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Pgr
|
progesterone receptor
|
multiple interactions
|
ISO
|
Camphor binds to and results in decreased activity of PGR protein
|
CTD |
PMID:27633901 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Runx2
|
RUNX family transcription factor 2
|
affects expression
|
ISO
|
Camphor analog affects the expression of RUNX2 mRNA
|
CTD |
PMID:24704097 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
G
|
Snai1
|
snail family transcriptional repressor 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:176,667,476...176,671,965
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sparc
|
secreted protein acidic and cysteine rich
|
affects expression
|
ISO
|
Camphor analog affects the expression of SPARC mRNA
|
CTD |
PMID:24704097 |
|
NCBI chr10:40,017,065...40,038,816
Ensembl chr10:40,017,075...40,039,268
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Trpv1
|
transient receptor potential cation channel, subfamily V, member 1
|
multiple interactions
|
EXP
|
Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein]
|
CTD |
PMID:18172555 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021
|
|
G
|
Trpv3
|
transient receptor potential cation channel, subfamily V, member 3
|
increases activity multiple interactions
|
ISO
|
Camphor results in increased activity of TRPV3 protein isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein]
|
CTD |
PMID:21353389 |
|
NCBI chr10:58,382,054...58,413,657
Ensembl chr10:58,382,054...58,411,800
|
|
G
|
Zeb1
|
zinc finger E-box binding homeobox 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745
|
|
G
|
Zeb2
|
zinc finger E-box binding homeobox 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:49,624,028...49,754,323
Ensembl chr 3:49,624,028...49,754,323
|
|
|
G
|
Casp3
|
caspase 3
|
increases activity
|
ISO
|
28-deoxonimbolide results in increased activity of CASP3 protein
|
CTD |
PMID:21381696 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases activity
|
ISO
|
28-deoxonimbolide results in increased activity of CASP8 protein
|
CTD |
PMID:21381696 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases activity
|
ISO
|
28-deoxonimbolide results in increased activity of CASP9 protein
|
CTD |
PMID:21381696 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
|
G
|
Casp3
|
caspase 3
|
increases activity
|
ISO
|
azadiradione results in increased activity of CASP3 protein
|
CTD |
PMID:21381696 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases activity
|
ISO
|
azadiradione results in increased activity of CASP8 protein
|
CTD |
PMID:21381696 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases activity
|
ISO
|
azadiradione results in increased activity of CASP9 protein
|
CTD |
PMID:21381696 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
increases expression
|
ISO
|
azadiradione results in increased expression of HSPA1A mRNA
|
CTD |
PMID:30309986 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979
|
|
|
G
|
Calml5
|
calmodulin-like 5
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of CALM4 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr17:71,304,326...71,305,245
Ensembl chr17:71,304,326...71,305,245
|
|
G
|
Casp14
|
caspase 14
|
increases expression affects localization
|
ISO
|
beta-damascenone results in increased expression of CASP14 mRNA beta-damascenone affects the localization of CASP14 protein
|
CTD |
PMID:22982537 |
|
NCBI chr 7:11,577,315...11,583,987
Ensembl chr 7:11,580,339...11,583,171
|
|
G
|
Ces3a
|
carboxylesterase 3a
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of CES3 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr19:49,902,312...49,910,484
|
|
G
|
Clca1
|
chloride channel accessory 1
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of CLCA1 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 2:236,599,022...236,624,714
Ensembl chr 2:236,599,022...236,624,714
|
|
G
|
Clca2
|
chloride channel accessory 2
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of CLCA2 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 2:236,655,419...236,682,669
Ensembl chr 2:236,639,545...236,685,129
|
|
G
|
Cyp17a1
|
cytochrome P450, family 17, subfamily a, polypeptide 1
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of CYP17A1 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974
|
|
G
|
Fcgbp
|
Fc gamma binding protein
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of FCGBP mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 1:92,502,461...92,540,658
Ensembl chr 1:92,499,498...92,540,658
|
|
G
|
Flg
|
filaggrin
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of FLG mRNA; beta-damascenone results in increased expression of FLG protein
|
CTD |
PMID:22982537 |
|
NCBI chr 2:181,583,801...181,596,464
Ensembl chr 2:181,583,808...181,595,968
|
|
G
|
Hrnr
|
hornerin
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of HRNR mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 2:181,650,772...181,663,633
|
|
G
|
Il20ra
|
interleukin 20 receptor subunit alpha
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of IL20RA mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 1:16,243,683...16,313,229
Ensembl chr 1:16,243,801...16,313,221
|
|
G
|
Il36rn
|
interleukin 36 receptor antagonist
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of IL36RN mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 3:27,442,679...27,449,306
Ensembl chr 3:27,442,709...27,449,306
|
|
G
|
Krt1
|
keratin 1
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of KRT1 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 7:134,855,311...134,860,537
Ensembl chr 7:134,855,313...134,860,537
|
|
G
|
Krt10
|
keratin 10
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of KRT10 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr10:84,834,865...84,839,160
Ensembl chr10:84,834,840...84,839,160
|
|
G
|
Lce1b
|
late cornified envelope 1B
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of LCE1B mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 2:180,951,824...180,953,140
|
|
G
|
Lce1f
|
late cornified envelope 1F
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of LCE1F mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 2:181,001,399...181,002,985
Ensembl chr 2:181,001,399...181,002,985
|
|
G
|
Lipm
|
lipase, family member M
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of LIPM mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 1:241,031,382...241,050,796
Ensembl chr 1:241,031,483...241,050,792
|
|
G
|
Loricrin
|
loricrin cornified envelope precursor protein
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of LORICRIN mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 2:180,253,674...180,256,572
Ensembl chr 2:180,253,674...180,256,572
|
|
G
|
Otop3
|
otopetrin 3
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of OTOP3 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr10:101,076,307...101,087,704
Ensembl chr10:101,076,210...101,087,697
|
|
G
|
Pla2g4f
|
phospholipase A2, group IVF
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of PLA2G4F mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 3:127,702,603...127,720,429
Ensembl chr 3:127,703,841...127,718,348
|
|
G
|
Plcxd1
|
phosphatidylinositol-specific phospholipase C, X domain containing 1
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of PLCXD1 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr12:52,238,450...52,241,884
Ensembl chr12:52,238,623...52,241,865
|
|
G
|
Sdr16c5
|
short chain dehydrogenase/reductase family 16C, member 5
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of SDR16C5 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 5:21,816,394...21,841,596
Ensembl chr 5:21,816,394...21,838,551
|
|
G
|
Susd2
|
sushi domain containing 2
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of SUSD2 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr20:13,016,960...13,024,264
Ensembl chr20:13,016,907...13,024,264
|
|
G
|
Tmprss4
|
transmembrane serine protease 4
|
increases expression
|
ISO
|
beta-damascenone results in increased expression of TMPRSS4 mRNA
|
CTD |
PMID:22982537 |
|
NCBI chr 8:54,372,805...54,405,157
Ensembl chr 8:54,372,805...54,405,157
|
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888
|
|
G
|
Acacb
|
acetyl-CoA carboxylase beta
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr12:48,026,394...48,138,214
Ensembl chr12:48,026,394...48,138,214
|
|
G
|
Acly
|
ATP citrate lyase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccn2
|
cellular communication network factor 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col1a2
|
collagen type I alpha 2 chain
|
affects expression
|
ISO
|
Camphor analog affects the expression of COL1A2 mRNA
|
CTD |
PMID:24704097 |
|
NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995
|
|
G
|
Cpt1a
|
carnitine palmitoyltransferase 1A
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326
|
|
G
|
Cpt2
|
carnitine palmitoyltransferase 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
decreases activity
|
EXP
|
Camphor results in decreased activity of CYP2B1 protein
|
CTD |
PMID:9242356 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
multiple interactions
|
ISO
|
Camphor inhibits the reaction [CYP2B6 protein results in increased hydrolysis of Bupropion]
|
CTD |
PMID:18611395 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Dgat1
|
diacylglycerol O-acyltransferase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016
|
|
G
|
Esr1
|
estrogen receptor 1
|
multiple interactions
|
ISO
|
Camphor binds to and results in increased activity of ESR1 protein
|
CTD |
PMID:27633901 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
Fasn
|
fatty acid synthase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
G
|
Foxo1
|
forkhead box O1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419
|
|
G
|
Gabra1
|
gamma-aminobutyric acid type A receptor subunit alpha 1
|
multiple interactions
|
ISO
|
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
|
CTD |
PMID:15588619 |
|
NCBI chr10:27,096,731...27,152,563
Ensembl chr10:27,096,740...27,152,442
|
|
G
|
Gabrb2
|
gamma-aminobutyric acid type A receptor subunit beta 2
|
multiple interactions
|
ISO
|
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
|
CTD |
PMID:15588619 |
|
NCBI chr10:27,438,127...27,657,680
Ensembl chr10:27,438,238...27,655,171
|
|
G
|
Gabrg2
|
gamma-aminobutyric acid type A receptor subunit gamma 2
|
multiple interactions
|
ISO
|
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]
|
CTD |
PMID:15588619 |
|
NCBI chr10:26,876,926...26,965,523
Ensembl chr10:26,876,926...26,965,523
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Mlycd
|
malonyl-CoA decarboxylase
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr19:64,356,582...64,372,447
Ensembl chr19:64,356,223...64,372,446
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO
|
Camphor inhibits the reaction [cinnamaldehyde results in increased activity of MPO protein]
|
CTD |
PMID:21466812 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Pgr
|
progesterone receptor
|
multiple interactions
|
ISO
|
Camphor binds to and results in decreased activity of PGR protein
|
CTD |
PMID:27633901 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Runx2
|
RUNX family transcription factor 2
|
affects expression
|
ISO
|
Camphor analog affects the expression of RUNX2 mRNA
|
CTD |
PMID:24704097 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
G
|
Snai1
|
snail family transcriptional repressor 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:176,667,476...176,671,965
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sparc
|
secreted protein acidic and cysteine rich
|
affects expression
|
ISO
|
Camphor analog affects the expression of SPARC mRNA
|
CTD |
PMID:24704097 |
|
NCBI chr10:40,017,065...40,038,816
Ensembl chr10:40,017,075...40,039,268
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Trpv1
|
transient receptor potential cation channel, subfamily V, member 1
|
multiple interactions
|
EXP
|
Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein]
|
CTD |
PMID:18172555 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021
|
|
G
|
Trpv3
|
transient receptor potential cation channel, subfamily V, member 3
|
increases activity multiple interactions
|
ISO
|
Camphor results in increased activity of TRPV3 protein isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein]
|
CTD |
PMID:21353389 |
|
NCBI chr10:58,382,054...58,413,657
Ensembl chr10:58,382,054...58,411,800
|
|
G
|
Zeb1
|
zinc finger E-box binding homeobox 1
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745
|
|
G
|
Zeb2
|
zinc finger E-box binding homeobox 2
|
multiple interactions
|
ISO
|
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA
|
CTD |
PMID:38000518 |
|
NCBI chr 3:49,624,028...49,754,323
Ensembl chr 3:49,624,028...49,754,323
|
|
|
G
|
Nr3c1
|
nuclear receptor subfamily 3, group C, member 1
|
multiple interactions
|
ISO
|
fenchone binds to and results in decreased activity of NR3C1 protein
|
CTD |
PMID:27633901 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO
|
fenchone binds to and results in decreased activity of PPARG protein
|
CTD |
PMID:27633901 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
friedelin inhibits the reaction [Ethanol results in increased expression of CASP3 protein]
|
CTD |
PMID:37939858 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
friedelin inhibits the reaction [Ethanol results in increased expression of PARP1 protein]
|
CTD |
PMID:37939858 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
friedelin inhibits the reaction [Ethanol results in increased expression of RELA protein]
|
CTD |
PMID:37939858 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which affects the susceptibility to Vinblastine; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [Verapamil results in increased activity of ABCB1 protein]
|
CTD |
PMID:16904803 PMID:18204840 PMID:24380838 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcb4
|
ATP binding cassette subfamily B member 4
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB4 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 4:26,106,895...26,164,440
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
multiple interactions increases activity
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC1 mRNA] Glycyrrhetinic Acid results in increased activity of ABCC1 protein [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which affects the susceptibility to Doxorubicin; [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which results in increased abundance of fluorexon
|
CTD |
PMID:18204840 PMID:28549656 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions
|
EXP
|
Glycyrrhetinic Acid inhibits the reaction [ABCC2 protein results in increased transport of estradiol-17 beta-glucuronide]
|
CTD |
PMID:18436619 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]
|
CTD |
PMID:18436619 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Abcg5
|
ATP binding cassette subfamily G member 5
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCG5 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376
|
|
G
|
Acat2
|
acetyl-CoA acetyltransferase 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Monocrotaline results in increased expression of ACTA2 protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Akr1c1
|
aldo-keto reductase family 1, member C1
|
decreases activity
|
ISO
|
Glycyrrhetinic Acid results in decreased activity of AKR1C1 protein
|
CTD |
PMID:12604236 |
|
NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247
|
|
G
|
Akr1c2
|
aldo-keto reductase family 1, member C2
|
decreases activity
|
ISO
|
Glycyrrhetinic Acid results in decreased activity of AKR1C2 protein
|
CTD |
PMID:12604236 |
|
NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686
|
|
G
|
Akr1c3
|
aldo-keto reductase family 1, member C3
|
affects activity decreases activity
|
ISO
|
18alpha-glycyrrhetinic acid affects the activity of AKR1C3 protein Glycyrrhetinic Acid results in decreased activity of AKR1C3 protein
|
CTD |
PMID:11165023 PMID:12604236 |
|
NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438
|
|
G
|
Alb
|
albumin
|
multiple interactions
|
ISO
|
ALB protein binds to and affects the transport of Glycyrrhetinic Acid
|
CTD |
PMID:8831264 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Alpl
|
alkaline phosphatase, biomineralization associated
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]
|
CTD |
PMID:21910061 PMID:38244730 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167
|
|
G
|
Atf6
|
activating transcription factor 6
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ATF6 mRNA]
|
CTD |
PMID:35699857 |
|
NCBI chr13:85,460,312...85,639,959
Ensembl chr13:85,462,840...85,640,033
|
|
G
|
Atp8b1
|
ATPase phospholipid transporting 8B1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ATP8B1 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions decreases expression
|
EXP ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of BAX]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of BAX protein]; Glycyrrhetinic Acid promotes the reaction [bisphenol A results in increased expression of BAX protein] Glycyrrhetinic Acid results in decreased expression of BAX protein 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of BAX protein]
|
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 PMID:38348715 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions decreases expression
|
EXP ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in decreased expression of BCL2]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein] Glycyrrhetinic Acid results in decreased expression of BCL2 protein 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of BCL2 protein]
|
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 PMID:38348715 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bglap
|
bone gamma-carboxyglutamate protein
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318
|
|
G
|
Bmp2
|
bone morphogenetic protein 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of CASP3]
|
CTD |
PMID:35699857 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
ISO EXP
|
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA] Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in decreased activity of CAT protein]
|
CTD |
PMID:23341968 PMID:38348715 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of CDKN1B protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Csf2
|
colony stimulating factor 2
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]
|
CTD |
PMID:10460758 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031
|
|
G
|
Cxcr3
|
C-X-C motif chemokine receptor 3
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of CXCR3 mRNA]
|
CTD |
PMID:38244730 |
|
NCBI chr X:70,884,293...70,886,944
Ensembl chr X:70,883,958...70,886,871
|
|
G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions decreases expression
|
EXP
|
Glycyrrhetinic Acid inhibits the reaction [bisphenol A results in increased expression of CYCS protein] Glycyrrhetinic Acid results in decreased expression of CYCS protein
|
CTD |
PMID:38348715 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
EXP
|
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP1A2 protein
|
CTD |
PMID:21800547 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
EXP
|
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP2E1 protein
|
CTD |
PMID:21800547 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of EIF2AK3 mRNA]
|
CTD |
PMID:35699857 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268
|
|
G
|
Ern1
|
endoplasmic reticulum to nucleus signaling 1
|
multiple interactions
|
ISO EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of ERN1 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ERN1 mRNA]
|
CTD |
PMID:29444456 PMID:35699857 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791
|
|
G
|
Ggt1
|
gamma-glutamyltransferase 1
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GGT1 protein]
|
CTD |
PMID:28414158 |
|
NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050
|
|
G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of GOT1 protein]
|
CTD |
PMID:38244730 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
EXP ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GPT protein] 18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of GPT protein]; Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of GPT protein]
|
CTD |
PMID:28414158 PMID:28549656 PMID:36807597 PMID:38244730 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Gpx2
|
glutathione peroxidase 2
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of GPX2 mRNA]
|
CTD |
PMID:23341968 |
|
NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of HMOX1 mRNA]
|
CTD |
PMID:28414158 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hras
|
HRas proto-oncogene, GTPase
|
decreases expression
|
ISO
|
Glycyrrhetinic Acid results in decreased expression of HRAS protein
|
CTD |
PMID:19958823 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590
|
|
G
|
Hsd11b1
|
hydroxysteroid 11-beta dehydrogenase 1
|
decreases activity
|
ISO
|
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B1 protein
|
CTD |
PMID:24135201 |
|
NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432
|
|
G
|
Hsd11b2
|
hydroxysteroid 11-beta dehydrogenase 2
|
decreases activity multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B2 protein Glycyrrhetinic Acid inhibits the reaction [tributyltin results in increased activity of HSD11B2 protein]; Glycyrrhetinic Acid inhibits the reaction [triphenyltin chloride results in increased activity of HSD11B2 protein]
|
CTD |
PMID:24135201 PMID:31927052 |
|
NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812
|
|
G
|
Hsd3b1
|
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1
|
multiple interactions
|
ISO
|
[Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein
|
CTD |
PMID:25526675 |
|
NCBI chr 2:188,858,574...188,864,694
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of HSPA5 mRNA]
|
CTD |
PMID:35699857 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO EXP
|
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of IL1B protein]
|
CTD |
PMID:10460758 PMID:23373965 PMID:28414158 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]
|
CTD |
PMID:21644799 PMID:23373965 PMID:24849676 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Irak1
|
interleukin-1 receptor-associated kinase 1
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr X:156,919,927...156,929,825
Ensembl chr X:156,920,081...156,929,825
|
|
G
|
Irak3
|
interleukin-1 receptor-associated kinase 3
|
multiple interactions increases expression
|
ISO
|
[Glycyrrhetinic Acid co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IRAK3 mRNA; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] Glycyrrhetinic Acid results in increased expression of IRAK3 protein
|
CTD |
PMID:28213090 |
|
NCBI chr 7:57,538,522...57,600,166
Ensembl chr 7:57,539,557...57,598,706
|
|
G
|
Ly96
|
lymphocyte antigen 96
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr 5:7,365,536...7,397,864
Ensembl chr 5:7,365,557...7,395,816
|
|
G
|
Map3k5
|
mitogen-activated protein kinase kinase kinase 5
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of MAP3K5 protein]
|
CTD |
PMID:29444456 |
|
NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:16,505,596...16,723,898
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:23373965 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:23373965 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
|
CTD |
PMID:24613819 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of MPO protein]
|
CTD |
PMID:36807597 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mttp
|
microsomal triglyceride transfer protein
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions increases expression
|
ISO EXP
|
[Glycyrrhetinic Acid results in increased expression of NFE2L2] which results in decreased susceptibility to Carbon Tetrachloride; Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride affects the localization of NFE2L2 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]
|
CTD |
PMID:23341968 PMID:28414158 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]
|
CTD |
PMID:24613819 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of NFKBIA protein]
|
CTD |
PMID:23373965 PMID:24613819 PMID:28213090 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]
|
CTD |
PMID:21644799 PMID:23373965 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Npc1l1
|
NPC1 like intracellular cholesterol transporter 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr14:85,285,387...85,305,050
Ensembl chr14:85,285,390...85,305,050
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
EXP
|
glycyrrhetinic acid inhibits the reaction [1-naphthyl isothiocyanate decreases expression of Nr1h4 mRNA in liver]
|
RGD |
PMID:30061734 |
RGD:15092071 |
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Pdgfb
|
platelet derived growth factor subunit B
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of BAX protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in decreased expression of CDKN1B protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of BCL2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PPP1R12A protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343
|
|
G
|
Pik3cd
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
|
decreases activity
|
ISO
|
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CD protein
|
CTD |
PMID:21644799 |
|
NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968
|
|
G
|
Pik3cg
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma
|
decreases activity
|
ISO
|
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CG protein
|
CTD |
PMID:21644799 |
|
NCBI chr 6:54,494,247...54,529,563
Ensembl chr 6:54,478,603...54,529,509
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG protein]
|
CTD |
PMID:28414158 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ppp1r12a
|
protein phosphatase 1, regulatory subunit 12A
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PPP1R12A protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:45,369,315...45,480,157
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]
|
CTD |
PMID:21644799 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]
|
CTD |
PMID:23373965 PMID:24613819 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Ren
|
renin
|
decreases activity
|
ISO
|
Glycyrrhetinic Acid results in decreased activity of REN protein
|
CTD |
PMID:20460744 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543
|
|
G
|
Rhoa
|
ras homolog family member A
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RHOA protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302
|
|
G
|
Rock1
|
Rho-associated coiled-coil containing protein kinase 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK1 protein]
|
CTD |
PMID:31325423 |
|
NCBI chr18:1,387,360...1,509,218
Ensembl chr18:1,387,360...1,509,147
|
|
G
|
Rock2
|
Rho-associated coiled-coil containing protein kinase 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of ROCK2 protein]
|
CTD |
PMID:31325423 |
|
NCBI chr 6:45,407,823...45,502,773
Ensembl chr 6:45,407,965...45,502,771
|
|
G
|
Rorc
|
RAR-related orphan receptor C
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Ethinyl Estradiol results in increased expression of RORC mRNA]
|
CTD |
PMID:38244730 |
|
NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:184,698,818...184,724,566
|
|
G
|
Runx2
|
RUNX family transcription factor 2
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
G
|
Slc51b
|
SLC51 subunit beta
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109
|
|
G
|
Slco1a4
|
solute carrier organic anion transporter family, member 1a4
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA]
|
CTD |
PMID:28549656 |
|
NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816
|
|
G
|
Sod3
|
superoxide dismutase 3
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of SOD3 mRNA]
|
CTD |
PMID:23341968 |
|
NCBI chr14:62,822,865...62,828,602
Ensembl chr14:62,811,177...62,829,125
|
|
G
|
Sp7
|
Sp7 transcription factor
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]
|
CTD |
PMID:21910061 |
|
NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:135,363,199...135,373,559
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of TNF protein] 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
|
CTD |
PMID:21644799 PMID:24613819 PMID:28213090 PMID:28414158 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
decreases expression
|
EXP
|
Glycyrrhetinic Acid results in decreased expression of TP53 protein
|
CTD |
PMID:38348715 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Traf6
|
TNF receptor associated factor 6
|
multiple interactions
|
ISO
|
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]
|
CTD |
PMID:28213090 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]
|
CTD |
PMID:24613819 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Xbp1
|
X-box binding protein 1
|
multiple interactions
|
ISO
|
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of XBP1 protein alternative form]
|
CTD |
PMID:29444456 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
increases expression multiple interactions
|
ISO
|
hyperforin results in increased expression of ABCB1; hyperforin results in increased expression of ABCB1 mRNA hyperforin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]
|
CTD |
PMID:15266218 PMID:16005588 PMID:24259679 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Alas1
|
5'-aminolevulinate synthase 1
|
increases expression
|
ISO
|
hyperforin results in increased expression of ALAS1 mRNA
|
CTD |
PMID:24259679 |
|
NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642
|
|
G
|
Bak1
|
BCL2-antagonist/killer 1
|
increases expression
|
ISO
|
hyperforin results in increased expression of BAK1 protein
|
CTD |
PMID:32485087 |
|
NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
decreases expression increases expression multiple interactions
|
EXP ISO
|
hyperforin results in decreased expression of BAX mRNA hyperforin results in increased expression of BAX protein hyperforin inhibits the reaction [aluminum maltolate results in increased expression of BAX mRNA]
|
CTD |
PMID:30481499 PMID:32485087 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions increases expression
|
ISO EXP
|
hyperforin inhibits the reaction [aluminum maltolate results in decreased expression of BCL2 mRNA] hyperforin results in increased expression of BCL2 mRNA
|
CTD |
PMID:30481499 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases cleavage decreases expression
|
ISO EXP
|
hyperforin inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CASP3 mRNA] hyperforin results in increased cleavage of CASP3 protein hyperforin results in decreased expression of CASP3 mRNA hyperforin inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CASP3 mRNA]; hyperforin inhibits the reaction [Propofol results in increased cleavage of CASP3 protein]
|
CTD |
PMID:30481499 PMID:32485087 PMID:36640868 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases cleavage
|
ISO
|
hyperforin results in increased cleavage of CASP8 protein
|
CTD |
PMID:32485087 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression
|
ISO
|
hyperforin results in decreased expression of CCND1 protein
|
CTD |
PMID:32485087 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cflar
|
CASP8 and FADD-like apoptosis regulator
|
decreases expression
|
ISO
|
hyperforin results in decreased expression of CFLAR protein
|
CTD |
PMID:32485087 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434
|
|
G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions decreases expression
|
EXP ISO
|
hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CYCS protein] hyperforin results in decreased expression of CYCS protein
|
CTD |
PMID:30481499 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions decreases activity
|
ISO
|
hyperforin inhibits the reaction [CYP1A1 protein affects the metabolism of benzo(a)pyrene 7,8-dihydrodiol] hyperforin results in decreased activity of CYP1A1 protein
|
CTD |
PMID:14633740 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp24a1
|
cytochrome P450, family 24, subfamily a, polypeptide 1
|
increases expression
|
ISO
|
hyperforin results in increased expression of CYP24A1 mRNA
|
CTD |
PMID:15630458 |
|
NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
increases expression
|
ISO
|
hyperforin results in increased expression of CYP2B6 mRNA
|
CTD |
PMID:24259679 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression multiple interactions decreases activity
|
ISO
|
hyperforin results in increased expression of CYP3A4; hyperforin results in increased expression of CYP3A4 mRNA hyperforin results in increased expression of and results in increased activity of CYP3A4 protein hyperforin results in decreased activity of CYP3A4 protein
|
CTD |
PMID:15100173 PMID:15266218 PMID:16005588 PMID:16442130 PMID:17954527 PMID:24259679 More...
|
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
increases expression
|
ISO
|
hyperforin results in increased expression of CYP3A5 mRNA
|
CTD |
PMID:24259679 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
decreases expression
|
ISO
|
hyperforin results in decreased expression of CYP7A1 mRNA
|
CTD |
PMID:24259679 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
decreases phosphorylation
|
ISO
|
hyperforin results in decreased phosphorylation of EGFR protein
|
CTD |
PMID:32485087 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Fas
|
Fas cell surface death receptor
|
increases expression
|
ISO
|
hyperforin results in increased expression of FAS protein
|
CTD |
PMID:32485087 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104
|
|
G
|
Faslg
|
Fas ligand
|
increases expression
|
ISO
|
hyperforin results in increased expression of FASLG protein
|
CTD |
PMID:32485087 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
increases expression
|
ISO
|
hyperforin results in increased expression of ICAM1 mRNA
|
CTD |
PMID:15622447 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
ISO
|
hyperforin promotes the reaction [JUN protein binds to CXCL8 promoter]
|
CTD |
PMID:15622447 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation decreases phosphorylation
|
ISO
|
hyperforin results in increased phosphorylation of MAPK1 protein hyperforin results in decreased phosphorylation of MAPK1 protein
|
CTD |
PMID:15622447 PMID:32485087 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation decreases phosphorylation
|
ISO
|
hyperforin results in increased phosphorylation of MAPK3 protein hyperforin results in decreased phosphorylation of MAPK3 protein
|
CTD |
PMID:15622447 PMID:32485087 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mcl1
|
MCL1 apoptosis regulator, BCL2 family member
|
decreases expression
|
ISO
|
hyperforin results in decreased expression of MCL1 protein
|
CTD |
PMID:32485087 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions increases response to substance affects binding increases activity
|
ISO
|
[NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin binds to and results in increased activity of NR1I2 protein; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; NR1I2 protein affects the reaction [hyperforin results in increased expression of CYP2C9 mRNA]; NR1I2 protein promotes the reaction [hyperforin results in increased abundance of Lipids] hyperforin binds to NR1I2 protein hyperforin results in increased activity of NR1I2 protein
|
CTD |
PMID:14600250 PMID:15630458 PMID:15856409 PMID:20079722 PMID:26187274 PMID:26920453 PMID:27071811 More...
|
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Por
|
cytochrome p450 oxidoreductase
|
increases expression
|
ISO
|
hyperforin results in increased expression of POR mRNA
|
CTD |
PMID:24259679 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
G
|
Slc22a1
|
solute carrier family 22 member 1
|
decreases expression multiple interactions
|
ISO
|
hyperforin results in decreased expression of SLC22A1 protein [NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]
|
CTD |
PMID:26920453 |
|
NCBI chr 1:50,624,339...50,651,437
Ensembl chr 1:50,624,377...50,651,436
|
|
G
|
Trpc6
|
transient receptor potential cation channel, subfamily C, member 6
|
multiple interactions
|
EXP
|
hyperforin inhibits the reaction [Propofol results in decreased expression of TRPC6 protein]
|
CTD |
PMID:36640868 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304
|
|
G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
increases expression
|
ISO
|
hyperforin results in increased expression of UGT1A1 mRNA
|
CTD |
PMID:24259679 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Xiap
|
X-linked inhibitor of apoptosis
|
decreases expression
|
ISO
|
hyperforin results in decreased expression of XIAP protein
|
CTD |
PMID:32485087 |
|
NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978
|
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
multiple interactions
|
ISO
|
lactucin affects the reaction [Dietary Fats affects the expression of ACACA protein]
|
CTD |
PMID:32023857 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888
|
|
G
|
Adam17
|
ADAM metallopeptidase domain 17
|
multiple interactions
|
ISO
|
lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of ADAM17 mRNA]; lactucin inhibits the reaction [Fatty Acids, Nonesterified results in increased expression of ADAM17 mRNA]
|
CTD |
PMID:36055749 |
|
NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
lactucin results in increased expression of and results in decreased phosphorylation of AKT1 protein lactucin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:33995112 PMID:36364182 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
ISO
|
lactucin results in increased expression of BAX protein
|
CTD |
PMID:36364182 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions decreases expression
|
ISO
|
Acetylcysteine inhibits the reaction [lactucin results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [lactucin results in decreased expression of BCL2 protein] lactucin results in decreased expression of BCL2 mRNA; lactucin results in decreased expression of BCL2 protein
|
CTD |
PMID:34302634 PMID:36364182 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage
|
ISO
|
lactucin results in increased cleavage of CASP3 protein
|
CTD |
PMID:34302634 PMID:36364182 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Ccnb1
|
cyclin B1
|
decreases expression
|
ISO
|
lactucin results in decreased expression of CCNB1 protein
|
CTD |
PMID:36364182 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression
|
ISO
|
lactucin results in decreased expression of CCND1 protein
|
CTD |
PMID:36364182 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cd36
|
CD36 molecule
|
multiple interactions
|
ISO
|
lactucin affects the reaction [Dietary Fats affects the expression of CD36 mRNA]
|
CTD |
PMID:32023857 |
|
NCBI chr 4:18,209,088...18,302,142
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
decreases expression
|
ISO
|
lactucin results in decreased expression of CDK2 protein
|
CTD |
PMID:36364182 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
G
|
Cdk4
|
cyclin-dependent kinase 4
|
decreases expression
|
ISO
|
lactucin results in decreased expression of CDK4 protein
|
CTD |
PMID:36364182 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
lactucin results in increased expression of CDKN1A protein
|
CTD |
PMID:36364182 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cebpa
|
CCAAT/enhancer binding protein alpha
|
multiple interactions
|
ISO
|
lactucin affects the reaction [Dietary Fats affects the expression of CEBPA mRNA]; lactucin affects the reaction [Dietary Fats affects the expression of CEBPA protein]
|
CTD |
PMID:32023857 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
multiple interactions
|
ISO
|
lactucin affects the reaction [Dietary Fats affects the expression of CEBPB protein]
|
CTD |
PMID:32023857 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
G
|
Cflar
|
CASP8 and FADD-like apoptosis regulator
|
multiple interactions
|
ISO
|
Acetylcysteine inhibits the reaction [lactucin results in decreased expression of CFLAR protein]; CFLAR protein inhibits the reaction [lactucin results in increased cleavage of PARP1 protein]; lactucin results in decreased expression of and results in increased degradation of CFLAR protein
|
CTD |
PMID:34302634 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434
|
|
G
|
Dgat1
|
diacylglycerol O-acyltransferase 1
|
multiple interactions
|
ISO
|
lactucin affects the reaction [Dietary Fats affects the expression of DGAT1 mRNA]
|
CTD |
PMID:32023857 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016
|
|
G
|
Fas
|
Fas cell surface death receptor
|
multiple interactions
|
ISO
|
lactucin affects the reaction [Dietary Fats affects the expression of FAS protein]
|
CTD |
PMID:32023857 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
ISO
|
lactucin affects the reaction [Dietary Fats affects the activity of GPT protein]
|
CTD |
PMID:32023857 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Hadha
|
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha
|
multiple interactions
|
ISO
|
lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA mRNA]; lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA protein]; lactucin inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of HADHA mRNA]; lactucin inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of HADHA protein]
|
CTD |
PMID:36055749 |
|
NCBI chr 6:31,907,801...31,947,434
Ensembl chr 6:31,907,291...31,947,698
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
lactucin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
|
CTD |
PMID:33995112 PMID:39164375 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
lactucin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]
|
CTD |
PMID:33995112 PMID:39164375 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Jak2
|
Janus kinase 2
|
multiple interactions
|
ISO
|
lactucin affects the reaction [Dietary Fats affects the phosphorylation of JAK2 protein]
|
CTD |
PMID:32023857 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762
|
|
G
|
Ldha
|
lactate dehydrogenase A
|
affects binding
|
ISO
|
lactucin binds to LDHA protein
|
CTD |
PMID:36364182 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
multiple interactions
|
ISO
|
lactucin results in increased expression of and results in increased lipidation of MAP1LC3B protein
|
CTD |
PMID:36364182 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
lactucin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] lactucin results in increased expression of and results in decreased phosphorylation of MAPK1 protein
|
CTD |
PMID:33995112 PMID:36364182 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
lactucin results in increased expression of and results in decreased phosphorylation of MAPK3 protein lactucin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:33995112 PMID:36364182 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
|
CTD |
PMID:33995112 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases cleavage
|
ISO
|
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [lactucin results in increased cleavage of PARP1 protein]; CFLAR protein inhibits the reaction [lactucin results in increased cleavage of PARP1 protein]
|
CTD |
PMID:34302634 PMID:36364182 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pgm1
|
phosphoglucomutase 1
|
affects binding
|
ISO
|
lactucin binds to PGM1 protein
|
CTD |
PMID:36364182 |
|
NCBI chr 5:119,710,734...119,770,159
Ensembl chr 5:119,710,737...119,770,159
|
|
G
|
Pkm
|
pyruvate kinase M1/2
|
affects binding
|
ISO
|
lactucin binds to PKM protein
|
CTD |
PMID:36364182 |
|
NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO
|
lactucin affects the reaction [Dietary Fats affects the expression of PPARG mRNA]; lactucin affects the reaction [Dietary Fats affects the expression of PPARG protein]
|
CTD |
PMID:32023857 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
increases expression
|
ISO
|
lactucin results in increased expression of PTEN protein
|
CTD |
PMID:36364182 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; lactucin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
|
CTD |
PMID:33995112 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Smad3
|
SMAD family member 3
|
decreases expression
|
ISO EXP
|
lactucin results in decreased expression of SMAD3 protein
|
CTD |
PMID:39164375 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
G
|
Smad7
|
SMAD family member 7
|
increases expression
|
EXP ISO
|
lactucin results in increased expression of SMAD7 protein
|
CTD |
PMID:39164375 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:71,263,508...71,291,849
|
|
G
|
Sqstm1
|
sequestosome 1
|
multiple interactions
|
ISO
|
lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of SQSTM1 mRNA]; lactucin inhibits the reaction [Fatty Acids, Nonesterified results in increased expression of SQSTM1 mRNA]
|
CTD |
PMID:36055749 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
decreases localization multiple interactions
|
EXP ISO
|
lactucin results in decreased localization of STAT3 protein; lactucin results in decreased localization of STAT3 protein modified form lactucin affects the reaction [Dietary Fats affects the phosphorylation of STAT3 protein]
|
CTD |
PMID:32023857 PMID:39164375 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
decreases expression
|
EXP ISO
|
lactucin results in decreased expression of TGFB1 protein
|
CTD |
PMID:39164375 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tlr4
|
toll-like receptor 4
|
increases expression
|
EXP
|
lactucin results in increased expression of TLR4 protein
|
CTD |
PMID:39164375 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
lactucin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]
|
CTD |
PMID:39164375 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression
|
ISO
|
lactucin results in increased expression of TP53 protein
|
CTD |
PMID:36364182 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression
|
ISO
|
lucidenic acid N analog results in increased expression of HMOX1 protein
|
CTD |
PMID:25239868 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
|
G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
multiple interactions
|
ISO
|
omaveloxolone analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of ADIPOQ protein]
|
CTD |
PMID:32410268 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169
|
|
G
|
Fth1
|
ferritin heavy chain 1
|
multiple interactions
|
ISO
|
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]
|
CTD |
PMID:32410268 |
|
NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
ISO
|
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased expression of GPT protein
|
CTD |
PMID:32410268 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Lep
|
leptin
|
multiple interactions
|
ISO
|
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of LEP protein]
|
CTD |
PMID:32410268 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions
|
ISO
|
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; [omaveloxolone co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]
|
CTD |
PMID:32410268 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Srxn1
|
sulfiredoxin 1
|
multiple interactions
|
ISO
|
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]
|
CTD |
PMID:32410268 |
|
NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765
|
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
affects activity
|
ISO
|
rubiarbonone C affects the activity of CYP3A4 protein
|
CTD |
PMID:30259074 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp4f18
|
cytochrome P450, family 4, subfamily f, polypeptide 18
|
decreases activity multiple interactions
|
ISO
|
rubiarbonone C results in decreased activity of CYP4F3 protein alternative form rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid]
|
CTD |
PMID:30259074 |
|
NCBI chr16:17,797,558...17,838,958
Ensembl chr16:17,740,001...17,838,958
|
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of and results in increased cleavage of CASP3 protein]
|
CTD |
PMID:34732784 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cdh1
|
cadherin 1
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [Bleomycin results in decreased expression of CDH1 mRNA]; geranylgeranylacetone inhibits the reaction [Bleomycin results in decreased expression of CDH1 protein] geranylgeranylacetone inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 mRNA]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]
|
CTD |
PMID:37307957 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]
|
CTD |
PMID:37307957 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col1a2
|
collagen type I alpha 2 chain
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of COL1A2 mRNA]; geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of COL1A2 protein]
|
CTD |
PMID:37307957 |
|
NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995
|
|
G
|
Dlg1
|
discs large MAGUK scaffold protein 1
|
increases expression multiple interactions
|
ISO
|
geranylgeranylacetone results in increased expression of DLG1 mRNA; geranylgeranylacetone results in increased expression of DLG1 protein geranylgeranylacetone promotes the reaction [[HSF1 protein binds to DLG1 promoter] which results in increased expression of DLG1 mRNA]; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA]; resveratrol promotes the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA]
|
CTD |
PMID:21232033 |
|
NCBI chr11:82,416,853...82,607,797
Ensembl chr11:82,416,853...82,607,797
|
|
G
|
Edn1
|
endothelin 1
|
decreases expression
|
EXP
|
geranylgeranylacetone results in decreased expression of EDN1 protein
|
CTD |
PMID:16324314 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Fn1
|
fibronectin 1
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of FN1 mRNA]; geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of FN1 protein]
|
CTD |
PMID:37307957 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137
|
|
G
|
Hsf1
|
heat shock transcription factor 1
|
multiple interactions affects response to substance increases expression
|
ISO
|
geranylgeranylacetone promotes the reaction [[HSF1 protein binds to DLG1 promoter] which results in increased expression of DLG1 mRNA] HSF1 protein affects the susceptibility to geranylgeranylacetone geranylgeranylacetone results in increased expression of HSF1 protein
|
CTD |
PMID:17189318 PMID:21232033 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
multiple interactions
|
ISO
|
geranylgeranylacetone promotes the reaction [Bleomycin results in increased expression of HSPA1A mRNA]; geranylgeranylacetone promotes the reaction [Ethanol results in increased expression of HSPA1A protein] geranylgeranylacetone promotes the reaction [TGFB1 protein results in increased expression of HSPA1A mRNA]; geranylgeranylacetone promotes the reaction [TGFB1 protein results in increased expression of HSPA1A protein]
|
CTD |
PMID:17189318 PMID:37307957 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with geranylgeranylacetone] results in increased expression of HSPA1B mRNA; [Tetrachlorodibenzodioxin co-treated with geranylgeranylacetone] results in increased expression of HSPA1B protein; geranylgeranylacetone promotes the reaction [Bleomycin results in increased expression of HSPA1B mRNA] geranylgeranylacetone promotes the reaction [TGFB1 protein results in increased expression of HSPA1B mRNA]; geranylgeranylacetone promotes the reaction [TGFB1 protein results in increased expression of HSPA1B protein]
|
CTD |
PMID:15340226 PMID:37307957 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Kcna5
|
potassium voltage-gated channel subfamily A member 5
|
increases expression
|
ISO
|
geranylgeranylacetone results in increased expression of KCNA5 protein
|
CTD |
PMID:21232033 |
|
NCBI chr 4:161,040,853...161,044,311
Ensembl chr 4:160,996,950...161,044,408
|
|
G
|
Map3k5
|
mitogen-activated protein kinase kinase kinase 5
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MAP3K5 protein]
|
CTD |
PMID:34732784 |
|
NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:16,505,596...16,723,898
|
|
G
|
Nox4
|
NADPH oxidase 4
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of NOX4 mRNA]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of NOX4 protein] geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of NOX4 mRNA]
|
CTD |
PMID:37307957 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of PARP1 protein]
|
CTD |
PMID:34732784 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of RELA protein]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of RELA mRNA]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of RELA protein] geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of RELA mRNA]
|
CTD |
PMID:34732784 PMID:37307957 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 mRNA]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of NOX4 mRNA]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of NOX4 protein]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of RELA mRNA]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of RELA protein]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; geranylgeranylacetone promotes the reaction [TGFB1 protein results in increased expression of HSPA1A mRNA]; geranylgeranylacetone promotes the reaction [TGFB1 protein results in increased expression of HSPA1A protein]; geranylgeranylacetone promotes the reaction [TGFB1 protein results in increased expression of HSPA1B mRNA]; geranylgeranylacetone promotes the reaction [TGFB1 protein results in increased expression of HSPA1B protein]
|
CTD |
PMID:37307957 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Txn1
|
thioredoxin 1
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TXN mRNA]; geranylgeranylacetone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TXN protein]
|
CTD |
PMID:34732784 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307
|
|
G
|
Vim
|
vimentin
|
multiple interactions
|
ISO
|
geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of VIM mRNA]; geranylgeranylacetone inhibits the reaction [Bleomycin results in increased expression of VIM protein] geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; geranylgeranylacetone inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]
|
CTD |
PMID:37307957 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|